Syndax Pharmaceuticals Inc (SNDX) concluded trading on Thursday at a closing price of $14.10, with 3.0 million shares of worth about $42.26 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -21.93% during that period and on March 20, 2025 the price saw a gain of about 7.47%. Currently the company’s common shares owned by public are about 85.69M shares, out of which, 84.15M shares are available for trading.
Stock saw a price change of 7.63% in past 5 days and over the past one month there was a price change of -4.41%. Year-to-date (YTD), SNDX shares are showing a performance of 6.66% which decreased to -35.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.06 but also hit the highest price of $25.07 during that period. The average intraday trading volume for Syndax Pharmaceuticals Inc shares is 2.34 million. The stock is currently trading -0.49% below its 20-day simple moving average (SMA20), while that difference is down -0.86% for SMA50 and it goes to -20.46% lower than SMA200.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) currently have 85.69M outstanding shares and institutions hold larger chunk of about 111.94% of that.
The stock has a current market capitalization of $1.21B and its 3Y-monthly beta is at 1.25. It has posted earnings per share of -$3.73 in the same period. It has Quick Ratio of 5.82 while making debt-to-equity ratio of 1.20. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SNDX, volatility over the week remained 5.21% while standing at 6.40% over the month.
Stock’s fiscal year EPS is expected to drop by -3.14% while it is estimated to increase by 26.95% in next year. EPS is likely to grow at an annualized rate of 27.23% for next 5-years, compared to annual growth of -15.16% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on October 24, 2024 offering a Buy rating for the stock and assigned a target price of $37 to it. Coverage by Jefferies stated Syndax Pharmaceuticals Inc (SNDX) stock as a Buy in their note to investors on June 28, 2024, suggesting a price target of $37 for the stock. On January 31, 2024, Scotiabank Downgrade their recommendations, while on December 22, 2023, Mizuho Initiated their ratings for the stock with a price target of $45. Stock get a Buy rating from BofA Securities on October 25, 2023.
